Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05267470 |
| Title | A Study of Bemarituzumab Monotherapy and Docetaxel Combination in Participants With Squamous Non-small-cell Lung Cancer (SqNSCLC) With Fibroblast Growth Factor Receptor Isoform 2b (FGFR2b) Overexpression (FORTITUDE-201) |
| Acronym | FORTITUDE-201 |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Amgen |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | POL | FRA | ESP | BEL |